BeiGene announced that the U.S. FDA has granted accelerated approval to BRUKINSA for the treatment of adult patients with relapsed or refractory follicular lymphoma, in combination with the anti-CD20 monoclonal antibody obinutuzumab, after two or more lines of systemic therapy. The indication is approved under accelerated approval based on response rate and durability of response, marking BRUKINSA’s fifth indication in B-cell malignancies in the U.S.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BGNE:
- BeiGene announces new efficacy analysis comparing Brukinsa vs. Acalabrutinib
- BeiGene price target lowered to $345 from $350 at Guggenheim
- BeiGene price target raised to $235 from $224 at TD Cowen
- BeiGene’s Biologics License Application for tevimbra accepted by FDA
- BeiGene, Ltd.’s New Technology Risk – A Cause for Worry?
